Bris­tol-My­ers bags a new tu­mor mi­croen­vi­ron­ment drug for next-gen can­cer com­bos

A lit­tle more than three years ago, Gen­mab out­li­censed its Hu­Max IL-8 tar­get­ing an­ti­body to lit­tle Cor­morant Phar­ma­ceu­ti­cals in Stock­holm. Over re­cent years, in­ves­ti­ga­tors have …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER